P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE P...

por Schjesvold, F, Ludwig, H, Delimpasi, S, Robak, P, Mateos, M, Sandberg, A, Thuresson, M, Norin, S, Richardson, P, Sonneveld, P
Publicado 2023

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DAR...

por Terpos, Evangelos, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Dialoupi, Ioanna, Verrou, Evgenia, Manousou, Kyriaki, Gkolfinopoulos, Stavros, Migkou, Magdalini, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios A.
Publicado 2023

P22: A NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE; INTERIM RESULTS...

por Katodritou, E, Kyrtsonis, MC, Delimpasi, S, Spanoudakis, E, Vassilopoulos, G, Zikos, P, Viniou, N, Kaiafa, G, Papathanasiou, M, Pappa, V, Michalis, E, Adamopoulos, I, Kokoviadou, K, Tsirakis, G, Poziopoulos, C, Terpos, E
Publicado 2022

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY

por Terpos, E, Ntanasis-Stathopoulos, I, Kastritis, E, Hatjiharissi, E, Katodritou, E, Eleutherakis-Papaiakovou, E, Verrou, E, Gavriatopoulou, M, Leonidakis, A, Delimpasi, S, Malandrakis, P, Kyrtsonis, M-C, Papaioannou, M, Symeonidis, A, Dimopoulos, MA
Publicado 2022

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”

por Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Hatjiharissi, Evdoxia, Katodritou, Eirini, Eleutherakis-Papaiakovou, Evangelos, Verrou, Evgenia, Gavriatopoulou, Maria, Leonidakis, Alexandros, Manousou, Kyriaki, Delimpasi, Sosana, Malandrakis, Panagiotis, Kyrtsonis, Marie-Christine, Papaioannou, Maria, Symeonidis, Argiris, Dimopoulos, Meletios-Athanasios
Publicado 2022

PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY M...

por Delimpasi, S., Quach, H., Cavo, M., Ho, P. J., Lee, C. H.-S., Santoro, A., Schots, R., Vlummens, P., Yoon, D. H., Yoon, S.-S., Santos, C. D., Samineni, D., Huang, J., Wehrman, K., Patil, U., Sheikh, S., Dimopoulos, M. A.
Publicado 2022

S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULT...

por Dimopoulos, Meletios A., Hungria, Vania, Radinoff, Atanas, Delimpasi, Sosana, Mikala, Gabor, Masszi, Tamas, LI, Jian, Capra, Marcelo Eduardo, Matsumoto, Morio, Sule, Neal, LI, Mary, Mckeown, Astrid, He, Wei, Bright, Shelley, Currie, Brooke, Boyle, Julia, Opalinska, Joanna, Weisel, Katja
Publicado 2023

P897: EVALUATION OF THE PROGNOSTIC IMPACT OF SECOND LINE ANTI-MYELOMA TREATMENTS ON POST- PROGRESSION OUTCOMES IN THE REAL-WORLD SETTING: THE GREEK MYELOMA STUDY GROUP EXPERIENCE.

por Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Theodorakakou, Fotini, Delimpasi, Sosana, Spanoudakis, Emmanouil, Ntanasis-Stathopoulos, Ioannis, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Triantafyllou, Theodora, Daiou, Aikaterini, Labropoulou, Vasiliki, Pouli, Anastasia, Roussou, Maria, Gavriatopoulou, Maria, Verrou, Evgenia, Dimopoulos, Meletios A., Terpos, Evangelos
Publicado 2023

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

por Dimopoulos, Meletios A., Moreau, Philippe, Augustson, Bradley, Castro, Nelson, Pika, Tomas, Delimpasi, Sosana, De la Rubia, Javier, Maiolino, Angelo, Reiman, Tony, Martinez‐Lopez, Joaquin, Martin, Thomas, Mikhael, Joseph, Yong, Kwee, Risse, Marie‐Laure, Asset, Gaelle, Marion, Sylvia, Hajek, Roman
Publicado 2022

P920: EVALUATION OF EARLY PROGRESSIVE DISEASE (EPD) IN NEWLY DIAGNOSED MYELOMA PATIENTS AND IDENTIFICATION OF PROGNOSTIC FACTORS IN THE ERA OF MODERN THERAPIES. THE GREEK MYELOMA S...

por Katodritou, Eirini, Kastritis, Efstathios, Dalampira, Dimitra, Theodorakakou, Fotini, Fotiou, Despina, Delimpasi, Sosana, Spanoudakis, Emmanouil, Ntanasis-Stathopoulos, Ioannis, Papadopoulou, Theodosia, Sevastoudi, Aggeliki, Triantafyllou, Theodora, Daiou, Aikaterini, Pouli, Anastasia, Migkou, Magdalini, Gavriatopoulou, Maria, Verrou, Evgenia, Christine Kyrtsonis, Marie, Dimopoulos, Meletios A., Terpos, Evangelos
Publicado 2023

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

por Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie‐Laure, van de Velde, Helgi, Richardson, Paul
Publicado 2021

P916: COEXISTENCE OF ≥2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE...

por Katodritou, E., Dalampira, D., Triantafyllou, T., Gavriatopoulou, M., Delimpasi, S., Pouli, A., Papadopoulou, T., Verrou, E., Sevastoudi, A., Tsirou, K., Katsika, L., Douganiotis, G., Karampatzakis, N., Metallinou, T.-E., Palaska, V., Kotsopoulou, M., Lalayianni, C., Kyrtsonis, M.-C., Spanoudakis, E., Maltezas, D., Chatzivasili, A., Dimopoulos, M.-A., Terpos, E., Kastritis, E.
Publicado 2022

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

por Katodritou, Eirini, Terpos, Evangelos, Delimpasi, Sossana, Kotsopoulou, Maria, Michalis, Eurydiki, Vadikolia, Chrysanthi, Kyrtsonis, Marie-Christine, Symeonidis, Argiris, Giannakoulas, Nikolaos, Vadikolia, Chrissa, Michael, Michalis, Kalpadakis, Christina, Gougopoulou, Theodora, Prokopiou, Chrystalla, Kaiafa, Georgia, Christoulas, Dimitrios, Gavriatopoulou, Maria, Giannopoulou, Evlampia, Labropoulou, Vasiliki, Verrou, Evgenia, Kastritis, Efstathios, Konstantinidou, Pavlina, Anagnostopoulos, Achilles, Dimopoulos, Meletios A.
Publicado 2018

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival

por Katodritou, Eirini, Kyrtsonis, Marie-Christine, Delimpasi, Sosana, Kyriakou, Despoina, Symeonidis, Argiris, Spanoudakis, Emmanouil, Vasilopoulos, Georgios, Anagnostopoulos, Achilles, Kioumi, Anna, Zikos, Panagiotis, Aktypi, Anthi, Briasoulis, Evangelos, Megalakaki, Aikaterini, Repousis, Panayiotis, Adamopoulos, Ioannis, Gogos, Dimitrios, Kotsopoulou, Maria, Pappa, Vassiliki, Papadaki, Eleni, Fotiou, Despoina, Nikolaou, Eftychia, Giannopoulou, Evlambia, Hatzimichael, Eleftheria, Giannakoulas, Nikolaos, Douka, Vassiliki, Kokoviadou, Kyriaki, Timotheatou, Despoina, Terpos, Evangelos
Publicado 2018

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

por Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian
Publicado 2021

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

por Richard, Shambavi, Chari, Ajai, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryna, Dimopoulos, Meletios A., Pylypenko, Halyna, Auner, Holger W., Leleu, Xavier, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don Ambrose, Quach, Hang, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, Badros, Ashraf, Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Mateos, Maria Victoria, Cavo, Michele, Chang, Hua, Landesman, Yosef, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Grosicki, Sebastian, Richardson, Paul G.
Publicado 2021